The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases

CT Chou, Hsien-Tzung Liao, CH Chen, WS Chen, HP Wang, KY Su

Research output: Contribution to journalArticle

Abstract

Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of early RA is quite impossible, as the clinical criteria are insufficient at the beginning stage of the disease. In 1998, Schelleken reported that a high percentage of RA patients had a specific antibody that could interact with a synthetic peptide which contained the amino acid citrulline. The high specificity (98%) for RA of this new serological marker, anti-cyclic citrullinated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.

Original languageEnglish
Pages (from-to)165-71
Number of pages7
JournalBiomarker Insights
Volume2
Publication statusPublished - 2007

Fingerprint

Rheumatic Diseases
Rheumatoid Arthritis
Antibodies
Citrulline
Antirheumatic Agents
Rheumatoid Factor
Sedimentation
Anti-Idiotypic Antibodies
C-Reactive Protein
Biological Therapy
Symptom Assessment
Amino Acids
Blood Sedimentation
Peptides
Serologic Tests
Ethnic Groups
Biomarkers

Keywords

  • Journal Article

Cite this

Chou, CT., Liao, H-T., Chen, CH., Chen, WS., Wang, HP., & Su, KY. (2007). The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases. Biomarker Insights, 2, 165-71.

The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases. / Chou, CT; Liao, Hsien-Tzung; Chen, CH; Chen, WS; Wang, HP; Su, KY.

In: Biomarker Insights, Vol. 2, 2007, p. 165-71.

Research output: Contribution to journalArticle

Chou, CT, Liao, H-T, Chen, CH, Chen, WS, Wang, HP & Su, KY 2007, 'The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases', Biomarker Insights, vol. 2, pp. 165-71.
Chou, CT ; Liao, Hsien-Tzung ; Chen, CH ; Chen, WS ; Wang, HP ; Su, KY. / The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases. In: Biomarker Insights. 2007 ; Vol. 2. pp. 165-71.
@article{cf6a7433143846e4b66c230bce86d3f3,
title = "The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases",
abstract = "Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of early RA is quite impossible, as the clinical criteria are insufficient at the beginning stage of the disease. In 1998, Schelleken reported that a high percentage of RA patients had a specific antibody that could interact with a synthetic peptide which contained the amino acid citrulline. The high specificity (98{\%}) for RA of this new serological marker, anti-cyclic citrullinated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.",
keywords = "Journal Article",
author = "CT Chou and Hsien-Tzung Liao and CH Chen and WS Chen and HP Wang and KY Su",
year = "2007",
language = "English",
volume = "2",
pages = "165--71",
journal = "Biomarker Insights",
issn = "1177-2719",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases

AU - Chou, CT

AU - Liao, Hsien-Tzung

AU - Chen, CH

AU - Chen, WS

AU - Wang, HP

AU - Su, KY

PY - 2007

Y1 - 2007

N2 - Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of early RA is quite impossible, as the clinical criteria are insufficient at the beginning stage of the disease. In 1998, Schelleken reported that a high percentage of RA patients had a specific antibody that could interact with a synthetic peptide which contained the amino acid citrulline. The high specificity (98%) for RA of this new serological marker, anti-cyclic citrullinated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.

AB - Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of early RA is quite impossible, as the clinical criteria are insufficient at the beginning stage of the disease. In 1998, Schelleken reported that a high percentage of RA patients had a specific antibody that could interact with a synthetic peptide which contained the amino acid citrulline. The high specificity (98%) for RA of this new serological marker, anti-cyclic citrullinated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.

KW - Journal Article

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717818/

M3 - Article

VL - 2

SP - 165

EP - 171

JO - Biomarker Insights

JF - Biomarker Insights

SN - 1177-2719

ER -